ASBESTOS LITIGATION: Alfacell to Explore Strategies for Onconase
April 3, 2009
Par Pharmaceuticals Companies, Inc. says that Alfacell Corporation intends to continue to explore strategic alternatives and additional capital for Onconase (ranpirnase), which is intended for the treatment of inoperable malignant mesothelioma, according to the Company’s 2008 annual report filed with…